Vincerx Pharma, Inc.
Vincerx Pharma, Inc. is grouped at the issuer level across 1 linked ticker lifecycle, combining public listing, delisting, source, and shareholder outcome records from the archive.
Lifecycle Map
Issuer enters the archive
Feb 14, 2020Vincerx Pharma, Inc. is represented as an issuer-level entity with 1 linked public-market ticker lifecycle.
Delisting event
Apr 28, 2025Removed from listing - SEC Form 25 filed.
SourceVINC stopped trading
Apr 28, 2025VINC is linked to Vincerx Pharma, Inc. and ended with final status "merged".
Source
Entity Graph
Vincerx Pharma, Inc.issuedVINC
VINClisted onNASDAQ
VINCresulted inmixed
Source-Backed Claims
- LifeSci Acquisition Corp. filed a definitive proxy statement on December 7, 2020, in accordance with Section 14(a) of the Securities Exchange Act of 1934.DEFM14A
- As of November 20, 2020, there were 8,204,709 shares of LifeSci Acquisition Corp. (LSAC) issued and outstanding that were entitled to vote.DEFM14A
- The proposed maximum aggregate value of the transaction was calculated based on $13.80 per share, totaling $75,900,000 for 5,500,000 shares of LSAC's common stock.DEFM14A
- A special meeting of stockholders of LifeSci Acquisition Corp. was scheduled for December 22, 2020, at 10:00 a.m. Eastern time.DEFM14A
- Holders of LSAC Shares were entitled to redeem their shares for a pro rata share of LSAC's Trust Account, estimated to be at least $10.00 per share, prior to the special meeting.DEFM14A
- The sellers in the business combination were entitled to receive $55 million of stock consideration upon completion of the merger.DEFM14A
- As of December 3, 2020, approximately $65.7 million remained in LSAC's trust account.DEFM14A
Associated Tickers
Public-market security lifecycles tied to this issuer record.